Business Context and Reporting Period
Company: Vyome Holdings, Inc. (Ticker: HIND)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Vyome is a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases. The company operates two segments: Biotechnology (development of drug candidates like VT-1953 for malignant fungating wounds) and Pharmaceutical (commercialization of antifungal products in India via Sun Pharma). The company completed a reverse merger with Reshape Lifesciences in August 2025 and is currently listed on the Nasdaq Capital Market.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (USD) |
|---|---|
| Revenue | $58,546 |
| Gross Profit | $28,303 |
| Operating Expenses | $2,020,809 |
| Operating Loss | $(1,992,506) |
| Net Loss | $(1,705,204) |
| Net Loss Attributable to Owners | $(1,648,466) |
| Cash and Cash Equivalents (Ending) | $7,887,510 |
| Total Assets | $9,176,362 |
| Total Liabilities | $1,864,656 |
| Stockholders' Equity | $7,311,706 |
Key Margins: Gross margin was approximately 48.3% ($28,303 / $58,546). The company reported a net loss margin of -2,912% due to high R&D and operating costs relative to minimal revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 76.4% to $58,546 from $248,535 in the prior year period. This was primarily due to the absence of a $116,900 milestone payment received in the prior year related to the Luliconazole licensing agreement.
- Expense Surge: Total operating expenses increased by 188% to $2.02 million. Research and Development (R&D) expenses jumped 589% to $1.17 million, driven by scaling regulatory consulting and CMC preparation for the lead candidate VT-1953. Selling, General, and Administrative (SG&A) expenses rose 60% to $842,466 due to public company compliance costs and increased staffing.
- Interest Income: Interest income and other income increased significantly to $293,472 from $1,035, driven by higher cash balances from merger proceeds and ATM financing.
- Debt Elimination: All convertible notes and promissory notes outstanding in the prior period were converted to equity during the August 2025 merger. Consequently, interest expense dropped to negligible levels ($6,170) compared to $111,093 in the prior period.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash resources ($7.9 million) combined with the ATM facility will fund operations for at least 15 months, including the initiation of the pivotal trial for VT-1953. However, the company explicitly states it will not be sufficient to complete the trial or develop other candidates without additional funding.
Regulatory Progress:
- VT-1953: Filed for Orphan Drug Designation (Jan 2026) and submitted a pre-IND briefing (Mar 2026). Received FDA written response in Q2 2026; planning a Type C meeting.
- VB-1953: Phase II trial for acne completed with positive read-outs; Phase III ready.
Risks and Contingencies:
- Going Concern: The company has a history of losses and requires additional financing to continue operations. Failure to raise capital could force delays in trials or cessation of operations.
- Legal/Tax Dispute: Indian GST authorities issued a demand order of approximately $750,000 (including interest/penalties) regarding a refund claim. The company is contesting this in the Delhi High Court and has not recorded a provision, believing a loss is not probable.
- Customer Concentration: Substantially all revenue is derived from a single customer, Sun Pharma, in India.
Investor Verification Checklist
- Cash Runway: Verify the 15-month runway estimate against current burn rates and the timeline for the VT-1953 pivotal trial.
- ATM Utilization: Monitor the remaining capacity of the $12 million ATM facility and the pricing of recent share sales (approx. $4.00–$6.00 range).
- Legal Exposure: Track the outcome of the Delhi High Court case regarding the $750,000 GST demand order.
- R&D Milestones: Confirm the schedule for the FDA Type C meeting and the subsequent initiation of the VT-1953 pivotal trial.
- Revenue Sustainability: Assess the long-term viability of the pharmaceutical segment given the loss of milestone payments and reliance on royalties from Sun Pharma.